Preventive treatment of chronic migraine with zonisamide: A study in patients who are refractory or intolerant to topiramate;Tratamiento preventivo de la migraña crónica con zonisamida: Un estudio en pacientes refractarios o intolerantes a topiramato

Revista de Neurologia

Volumn 47, Issue 9, 2008, Pages 449-451

  Pascual Gómez, Julio ^a   Alana Garcia M ^a   Oterino, A ^b   Leira, R ^c   Lainez Andres J M ^d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Chronic migraine; Topiramate; Zonisamide

Indexed keywords

TOPIRAMATE; ZONISAMIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 56049085830     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4709.2008503     Document Type: Article

References (19)

1. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638-45.
2. Pascual-Gómez J, Caminero-Rodríguez AB, Cano A, Heras-Pérez JA, Leira-Muiño R, García-Ribas G, grupo de investigadores participantes en el estudio PREVENTIA. Determinantes para el uso del tratamiento profiláctico de la migraña en España. Rev Neurol 2007; 45: 513-9.
3. Pascual J, Combarros O, Leno C, Polo JM, Rebollo M, Berciano J. Distribución por diagnósticos de la cefalea como motivo de consulta neurológica. Med Clin (Barc) 1995; 104: 161-4.
4. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23: 820-4.
5. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80.
6. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201 (TOP-CHROMR) Study Group. Topiramate reduces headache days in chronic migraine: a randomised, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-23.
7. Láinez-Andrés JM. Topiramato en la profilaxis de la migraña. Rev Neurol 2006; 43: 257-8.
8. Pascual J, Aguirre JJ, García-Moncó JC, Seijo M. Migraña y cefalea de tensión. In Mateos V, ed. Guía para el diagnóstico y tratamiento de las cefaleas. Barcelona: Prous Science; 2006. p. 37-66.
9. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2 ed. Cephalalgia 2004; 24 (Suppl 1): 9-160.
10. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004; 27: 278-80.
11. Smith TR. Treatment of refractory chronic daily headache with zonisamide: a case series. Cephalalgia 2001; 21: 482 [abstract].
12. Krusz JC. Zonisamide in the treatment of headache disorders. Cephalalgia 2001; 21: 374-5 [abstract].
13. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006; 26: 1199-202.
14. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomised controlled trial. JAMA 2004; 291: 965-73.
15. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
16. Pascual J, Polo JM, Berciano J. The dose of propranolol for migraine prophylaxis. Efficacy of low doses. Cephalalgia 1989; 9: 287-91.
17. Palkanis A, Kring D. Zonisamide prophylaxis in refractory pediatric patients. Headache 2006; 46: 804-7.
18. López-Trigo J, Ortiz-Sánchez P, Blanco-Hernández P. Zonisamida y dolor neuropático. Rev Neurol 2007; 45: 429-32.
19. Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005; 19: 347-67.